Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis

Journal of Immunology

Volumn 187, Issue 2, 2011, Pages 781-790

  Jiang, Wenzheng ^a,b   Chai, Noo Ri ^a   Maric, Dragan ^a   Bielekova, Bibiana ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD56 ANTIGEN; DACLIZUMAB; GRANZYME; GRANZYME A; GRANZYME K; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EFFECTOR CELL; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOREGULATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; T LYMPHOCYTE ACTIVATION;

ADAPTIVE IMMUNITY; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD56; CELL DEATH; CELL LINE; CELL LINE, TRANSFORMED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; GENE SILENCING; GRANZYMES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; T-LYMPHOCYTE SUBSETS;

EID: 79960547202     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100789     Document Type: Article

References (46)

1. Hafler, D. A., A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, P. I. de Bakker, S. B. Gabriel, D. B. Mirel, A. J. Ivinson, et al; International Multiple Sclerosis Genetics Consortium. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357: 851-862. (Pubitemid 47347319)
2. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192: 393-404.
3. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979.
4. Astier, A. L., G. Meiffren, S. Freeman, and D. A. Hafler. 2006. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 116: 3252-3257.
5. Zhang, B., T. Yamamura, T. Kondo, M. Fujiwara, and T. Tabira. 1997. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186: 1677-1687.
6. Smeltz, R. B., N. A. Wolf, and R. H. Swanborg. 1999. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J. Immunol. 163: 1390-1397.
7. Rabinovich, B. A., J. Li, J. Shannon, R. Hurren, J. Chalupny, D. Cosman, and R. G. Miller. 2003. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J. Immunol. 170: 3572-3576.
8. Benczur, M., G. G. Petrányl, G. Pálffy, M. Varga, M. Tálas, B. Kotsy, I. Földes, and S. R. Hollán. 1980. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin. Exp. Immunol. 39: 657-662.
9. Ilonen, J., T. Nurmi, M. Reunanen, and A. Salmi. 1987. NK activity and NK-like non-specific cytolysis after PPD, rubella and measles antigen stimulation in multiple sclerosis. J. Neurol. Sci. 77: 77-85.
10. Vranes, Z., Z. Poljaković, and M. Marusić. 1989. Natural killer cell number and activity in multiple sclerosis. J. Neurol. Sci. 94: 115-123.
11. Munschauer, F. E., L. A. Hartrich, C. C. Stewart, and L. Jacobs. 1995. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J. Neuroimmunol. 62: 177-181.
12. Kastrukoff, L. F., A. Lau, R. Wee, D. Zecchini, R. White, and D. W. Paty. 2003. Clinical relapses of multiple sclerosis are associated with "novel" valleys in natural killer cell functional activity. J. Neuroimmunol. 145: 103-114.
13. Kastrukoff, L. F., N. G. Morgan, T. M. Aziz, D. Zecchini, J. Berkowitz, and D. W. Paty. 1988. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. J. Neuroimmunol. 20: 15-23.
14. Kastrukoff, L. F., N. G. Morgan, D. Zecchini, R. White, A. J. Petkau, J. Satoh, and D. W. Paty. 1998. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J. Neuroimmunol. 86: 123-133.
15. Huang, D., F. D. Shi, S. Jung, G. C. Pien, J. Wang, T. P. Salazar-Mather, T. T. He, J. T. Weaver, H. G. Ljunggren, C. A. Biron, et al. 2006. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 20: 896-905. (Pubitemid 44943947)
16. Bielekova, B., N. Richert, T. Howard, G. Blevins, S. Markovic-Plese, J. McCartin, J. A. Frank, J. Würfel, J. Ohayon, T. A. Waldmann, et al. 2004. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc. Natl. Acad. Sci. USA 101: 8705-8708.
17. Rose, J. W., H. E. Watt, A. T. White, and N. G. Carlson. 2004. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56: 864-867.
18. Wynn, D., M. Kaufman, X. Montalban, T. Vollmer, J. Simon, J. Elkins, G. O'Neill, L. Neyer, J. Sheridan, C. Wang, et al; CHOICE investigators. 2010. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon β. Lancet Neurol. 9: 381-390.
19. bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103: 5941-5946.
20. Bielekova, B., T. Howard, A. N. Packer, N. Richert, G. Blevins, J. Ohayon, T. A. Waldmann, H. F. McFarland, and R. Martin. 2009. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 66: 483-489.
21. MacEwan, D. J. 2002. TNF ligands and receptors: a matter of life and death. Br. J. Pharmacol. 135: 855-875.
22. Chowdhury, D., and J. Lieberman. 2008. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 26: 389-420.
23. Catalfamo, M., and P. A. Henkart. 2003. Perforin and the granule exocytosis cytotoxicity pathway. Curr. Opin. Immunol. 15: 522-527.
24. Martinvalet, D., P. Zhu, and J. Lieberman. 2005. Granzyme A induces caspasein-dependent mitochondrial damage, a required first step for apoptosis. Immunity 22: 355-370. (Pubitemid 40387477)
25. Bovenschen, N., R. Quadir, A. L. van den Berg, A. B. Brenkman, I. Vandenberghe, B. Devreese, J. Joore, and J. A. Kummer. 2009. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. J. Biol. Chem. 284: 3504-3512.
26. Guo, Y., J. Chen, L. Shi, and Z. Fan. 2010. Valosin-containing protein cleavage by granzyme K accelerates an endoplasmic reticulum stress leading to caspasein-dependent cytotoxicity of target tumor cells. J. Immunol. 185: 5348-5359.
27. McQueen, K. L., and P. Parham. 2002. Variable receptors controlling activation and inhibition of NK cells. Curr. Opin. Immunol. 14: 615-621.
28. Ljunggren, H. G., and K. Kärre. 1990. In search of the "missing self": MHC molecules and NK cell recognition. Immunol. Today 11: 237-244.
29. Kärre, K., G. O. Klein, R. Kiessling, G. Klein, and J. C. Roder. 1980. Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature 284: 624-626.
30. Della Chiesa, M., M. Vitale, S. Carlomagno, G. Ferlazzo, L. Moretta, and A. Moretta. 2003. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. 33: 1657-1666.
31. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22: 633-640.
32. Bade, B., H. E. Boettcher, J. Lohrmann, C. Hink-Schauer, K. Bratke, D. E. Jenne, J. C. Virchow, Jr., and W. Luttmann. 2005. Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes. Int. Immunol. 17: 1419-1428.
33. + T cell differentiation in peripheral blood. Eur. J. Immunol. 35: 2608-2616.
34. bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon β. Neurol. Sci. 28: 121-126.
35. + Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 215: 125-128.
36. Feldmann, J., G. Ménasché, I. Callebaut, V. Minard-Colin, B. Bader-Meunier, L. Le Clainche, A. Fischer, F. Le Deist, M. Tardieu, and G. de Saint Basile. 2005. Severe and progressive encephalitis as a presenting manifestation of a novel missense perforin mutation and impaired cytolytic activity. Blood 105: 2658-2663.
37. Cappellano, G., E. Orilieri, C. Comi, A. Chiocchetti, S. Bocca, E. Boggio, I. S. Bernardone, A. Cometa, R. Clementi, N. Barizzone, et al. 2008. Variations of the perforin gene in patients with multiple sclerosis. Genes Immun. 9: 438-444.
38. Gong, J. H., G. Maki, and H. G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658.
39. Su, H. C., K. B. Nguyen, T. P. Salazar-Mather, M. C. Ruzek, M. Y. Dalod, and C. A. Biron. 2001. NK cell functions restrain T cell responses during viral infections. Eur. J. Immunol. 31: 3048-3055.
40. Hao, J., R. Liu, W. Piao, Q. Zhou, T. L. Vollmer, D. I. Campagnolo, R. Xiang, A. La Cava, L. Van Kaer, and F. D. Shi. 2010. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 207: 1907-1921.
41. Matsumoto, Y., K. Kohyama, Y. Aikawa, T. Shin, Y. Kawazoe, Y. Suzuki, and N. Tanuma. 1998. Role of natural killer cells and TCRγδ T cells in acute autoimmune encephalomyelitis. Eur. J. Immunol. 28: 1681-1688.
42. Baxter, A. G., and M. J. Smyth. 2002. The role of NK cells in autoimmune disease. Autoimmunity 35: 1-14.
43. French, A. R., and W. M. Yokoyama. 2004. Natural killer cells and autoimmunity. Arthritis Res. Ther. 6: 8-14.
44. bright subset. Blood 97: 3146-3151.
45. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101: 3052-3057.
46. Bajénoff, M., B. Breart, A. Y. Huang, H. Qi, J. Cazareth, V. M. Braud, R. N. Germain, and N. Glaichenhaus. 2006. Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. J. Exp. Med. 203: 619-631.